Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab in Axial Spondyloarthritis
NCT02429882Phase 2Withdrawn
- Sponsor
- Amgen
- Start
- May 2015
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of brodalumab in axial spondyloarthritis (axSpA), sponsored by Amgen. Planned start May 2015; status: withdrawn.
02
Drugs
brodalumab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NCT02429882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02429882.